This Treatment Improvement Protocol (TIP) reviews what is currently known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine (MA) and the misuse of prescribed stimulants (such as those for the treatment of attention defcit hyperactivity disorder [ADHD]). Read more
#ScaleUp is a new initiative of the United Nations Office on Drugs and Crime (UNODC). It builds on previous work and publications of UNODC, partner agencies and international researchers, such as the Discussion Paper on “Stimulant Use Disorders: Current Practices and Current Perspectives” (UNODC, 2019). This document calls for the scale up of effective psychosocial treatment, as well as increased research on pharmacological treatment options with a view to increase treatment engagement, treatment retention and effective treatment options for stimulant dependence. Read more
Mental, neurological and substance use (MNS) disorders are highly prevalent, accounting for a large burden of disease and disability globally. There remains a wide gap between available health systems capacity and resources, what is urgently needed, and what is available to reduce the burden. Nearly 1 in 10 people have a mental health disorder, but only 1% of the global health workforce provides mental health care. MNS disorders interfere, in substantial ways, with the ability of children to learn and the ability of adults to function in families, at work, and in society at large. Read more
The WHO Classification of digital interventions, services and applications in health (CDISAH) categorizes the different ways in which digital health interventions used in digital applications and services are used to address individual and health sector needs and advance health goals. Read more
The purpose for a Global Strategy on Digital Health is to promote healthy lives and wellbeing for everyone, everywhere, at all ages. To deliver its potential, national or regional Digital Health initiatives must be guided by a robust Strategy that integrates financial, organizational, human and technological resources. Read more
The American Society of Addiction Medicine (ASAM) and the American Academy of Addiction Psychiatry (AAAP) developed this Clinical Practice Guideline on the Management of Stimulant Use Disorder to provide evidence-based strategies and standards of care for the treatment of stimulant use disorders (StUDs), stimulant intoxication, and stimulant withdrawal, as well as secondary and tertiary prevention of harms associated with stimulant use. Read more
The year 2023 marks the midpoint of the work towards achieving the Sustainable Development Goals (SDGs). The global drug phenomenon continues to challenge both the implementation of SDG targets and efforts to promote peace, security and human rights. Read more
Amphetamine, methamphetamine and, more recently, synthetic cathinones are all synthetic central nervous system stimulants available on the drug market in Europe. On this page, you can find the latest analysis of the drug situation for synthetic stimulants in Europe, including prevalence of use, treatment demand, seizures, price and purity, harms and more. Read more
According to the report, coca cultivation soared 35 per cent from 2020 to 2021, a record high and the sharpest year-to-year increase since 2016. The steep growth in supply has been matched by a similar swelling in demand, with many regions showing a steady rise in cocaine users over the past decade. Read more
Constituting the fourth part of the World Drug Report 2022, this booklet focuses on the market dynamics of various stimulants – cocaine, amphetamines and “ecstasy” – and of NPS. Read more
